Study of FK463 for the Treatment of Invasive Aspergillosis

• Status: Completed
• Trial end date: 2002-01-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate the safety and efficacy of FK463 in patients with proven or probable invasive infections due to Aspergillus species.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Treatments: Micafungin

Criteria

Inclusion Criteria

• Has proven or probable systemic infection with Aspergillus species

Exclusion Criteria

• Has abnormal liver test parameters, e.g., AST or ALT > 10 times upper limit of normal

• Has bronchopulmonary aspergillosis, aspergillomas, sinus aspergillosis or external otitis but does not have histologic evidence of tissue invasion

• Has life-expectancy judged to be less than 5 days